Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dofetilide is mainly excreted unchanged in urine. Renal elimination involves both glomerular filtration and active tubular secretion (via cation transport system). Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with dofetilide. However, given the known QT prolongation risk associated with dofetilide, caution is recommended.